FIXX Homology Medicines Inc.

16.48
+0.3  (+2%)
Previous Close 16.17
Open 16.2
Price To Book 2.81
Market Cap 725,470,809
Shares 44,034,647
Volume 240,826
Short Ratio
Av. Daily Volume 369,793
Stock charts supplied by TradingView

NewsSee all news

  1. Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU

    - Well-Tolerated in First-in-Human AAVHSC Gene Therapy Trial - - Preliminary Data from First Patient in Second Cohort Showed Dose-Response with Observed Reductions from Baseline in Phe and Phe/Tyr Ratio and Increased

  2. Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care

    These Data Highlight Unmet Medical Need for Therapies to Control Phe Concentrations by Targeting the Underlying Cause of PKU BEDFORD, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a

  3. Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer

    - Experienced Clinical Geneticist with Track Record in Rare Disease Drug Development Joins Homology's Senior Management -  BEDFORD, Mass., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a

  4. Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs

    BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its proprietary adeno-associated viral

  5. Lyra Therapeutics Appoints Bradford Smith to its Board of Directors

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 initial data released December 17, 2019.
HMI-102
Phenylketonuria (PKU)

Latest News

  1. Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU

    - Well-Tolerated in First-in-Human AAVHSC Gene Therapy Trial - - Preliminary Data from First Patient in Second Cohort Showed Dose-Response with Observed Reductions from Baseline in Phe and Phe/Tyr Ratio and Increased

  2. Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care

    These Data Highlight Unmet Medical Need for Therapies to Control Phe Concentrations by Targeting the Underlying Cause of PKU BEDFORD, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a

  3. Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer

    - Experienced Clinical Geneticist with Track Record in Rare Disease Drug Development Joins Homology's Senior Management -  BEDFORD, Mass., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a

  4. Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs

    BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its proprietary adeno-associated viral

  5. Lyra Therapeutics Appoints Bradford Smith to its Board of Directors

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and